BAYTRIL 5%

Baytril 5% Injectable Solution is antibacterial broad-spectrum fluoroquinolone for management of bacterial pathogens, with activity against Gram-negative and Gram-positive bacteria.

Quinolone carboxylic acid derivatives are classified as DNA gyrase inhibitors. The mechanism of action of these compounds is very complex and not yet fully understood. The site of action is bacterial gyrase, a synthesis promoting enzyme. The effect on Escherichia coli is the inhibition of DNA synthesis through prevention of DNA supercoiling. Among other things, such compounds lead to the cessation of cell respiration and division. They may also interrupt bacterial membrane integrity.¹

Enrofloxacin is bactericidal, with activity against both Gram negative and Gram positive bacteria. The minimum inhibitory concentrations (MICs) were determined for a series of 39 isolates representing 9 genera of bacteria from natural infections in dogs and cats, selected principally because of resistance to one or more of the following antibiotics: ampicillin, cephalothin, colistin, chloramphenicol, erythromycin, gentamicin, kanamycin, penicillin, streptomycin, tetracycline, triple sulfa and sulfa/trimethoprim. The MIC values for enrofloxacin against these isolates are presented in Table I. Most strains of these organisms were found to be susceptible to enrofloxacin in vitro but the clinical significance has not been determined for some of the isolates.

Composition of BAYTRIL 5%

1 ml injectable solution contains 50 mg Enrofloxacin.

Indications for use
Enrofloxacin is a synthetic antiinfective of the fluoroquinolone class.

Baytril 5% injectable solution is indicated for the therapy of infectious diseases in cattle where clinical experience, supported where possible by sensitivity testing of the causal organisms, indicates Enrofloxacin as the drug of choice.

Respiratory and enteric diseases (Pasteurellosis, Mycoplasmosis, Colibacillosis, Colisepticaemia and secondary bacterial infections in crowding disease), Mastitis caused by susceptible microorganisms.

Baytril® is effective against the following microorganisms: Mycoplasma spp., E. coli, Salmonella spp.,Haemophilus spp., Pasteurella spp., Klebsiella spp., Proteus spp., Vibrio parahaemolyticusand Staphylococcus aureus.

Route of administration
For subcutaneous, intramuscular and intravenous administration.
Not more then 10ml should be administered at one i.m. or s.c. injection site.

Dosage
The dose rate is 2.5 mg  Enrofloxacin/ kg bw, (= 5 ml Baytril® 5% inj. solution / 100 kg bw)  For complicated respiratory disease this rate may be doubled to 5 mg / kg bw ( = 10 ml Baytril® 5% inj. solution / 100 kg bw).

Treatment interval
24 hours

Duration of treatment
3 – 5 days

Withdrawal period
Established for edible tissues and milk according to national regulations.